Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: A meta-analysis and system review

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Rao, Benqiang ^a   Han, Minyan ^a   Wang, Lei ^a   Gao, Xiaoyan ^a   Huang, Jun ^a   Huang, Meijin ^a   Liu, Huanliang ^a   Wang, Jianping ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE; EPITHELIAL CELL ADHESION MOLECULE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ID 3H1 ANTIBODY; MELANOMA ANTIGEN 3; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MURINE MONOCLONAL CARCINOEMBRYONIC ANTIGEN ANTIBODY; SART ICK CYB MULTI PEPTIDE VACCINE; SART3 PEPTIDE VACCINE; SURVIVE PEPTIDE VACCINE; TUMOR NECROSIS FACTOR ALPHA AUTOVACCINE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BLOOD PRESSURE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STAGING; COLORECTAL CARCINOMA; DIARRHEA; DISEASE FREE SURVIVAL; DRUG FEVER; ERYTHEMA; FATIGUE; FOLLOW UP; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; LYMPHADENOPATHY; MALAISE; META ANALYSIS; MINIMAL RESIDUAL DISEASE; NAUSEA; OVERALL SURVIVAL; PRURITUS; RIGOR; SIDE EFFECT; SYSTEMATIC REVIEW; TEMPERATURE; TREATMENT RESPONSE; ACTIVE IMMUNIZATION; COLORECTAL TUMOR; IMMUNOLOGY; PATHOLOGY; REVIEW; TREATMENT OUTCOME;

COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASM STAGING; NEOPLASM, RESIDUAL; TREATMENT OUTCOME;

EID: 79251536195     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-17     Document Type: Article

References (76)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Kerr D. Clinical development of gene therapy for colorectal cancer. Nat Rev Cancer 2003, 3:615-622. 10.1038/nrc1147, 12894249.
3. Lorenz M, Staib-Sebler E, Hochmuth K, Heinrich S, Gog C, Vetter G, Encke A, Muller HH. Surgical resection of liver metastases of colorectal carcinoma: short and long-term results. Semin Oncol 2000, 27:112-119.
4. Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet 2005, 365:153-165. 10.1016/S0140-6736(05)17706-X, 15639298.
5. Tebbutt NC, Cattell E, Midgley R, Cunningham D, Kerr D. Systemic treatment of colorectal cancer. Eur J Cancer 2002, 38:1000-1015. 10.1016/S0959-8049(02)00062-X, 11978525.
6. SEER Cancer Statistics Review, 1975-2003. 2006, National Cancer Institute, retrieved., http://seer.cancer.gov/csr/1975-2003/
7. Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst 2004, 96:1128-1132. 10.1093/jnci/djh220, 15292384.
8. Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, Nakamura S, Kakinuma S, Iwazaki S, Ishikawa H, Kawate S, Nakajima T, Morishita Y. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer 2004, 90:1003-1010. 10.1038/sj.bjc.6601619, 2409633, 14997197.
9. Wolmark N, Bryant J, Smith R, Grem J, Allegra C, Hyams D, Atkins J, Dimitrov N, Oishi R, Prager D, Fehrenbacher L, Romond E, Colangelo L, Fisher B. Adjuvant 5-uorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst 1998, 90:1810-1816. 10.1093/jnci/90.23.1810, 9839521.
10. Morse M, Langer L, Starodub A, Hobeika A, Clay T, Lyerly HK. Current Immunotherapeutic Strategies in Colon Cancer. Surg Oncol Clin N Am 2007, 16:873-900. 10.1016/j.soc.2007.07.005, 18022550.
11. Mocellin S, Mandruzzato S, Bronte V, Marincola FM. Cancer vaccines: pessimism in check. Nat Med 2004, 10:1278-1279. 10.1038/nm1204-1278, 15580242.
12. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915. 10.1038/nm1100, 1435696, 15340416.
13. Nagorsen D, Thiel E. Clinical and Immunologic Responses to Active Specific Cancer Vaccines in Human Colorectal Cancer. Clin Cancer Res 2006, 12:3064-3069. 10.1158/1078-0432.CCR-05-2788, 16707603.
14. Alejandro R, Jadad MD, DPhil R, Andrew Moore D, Dawn Carroll RGN, Crispin Jenkinson DPhil D, John M, Reynolds D, David J, Gavaghan D, Henry J, McQuay DM. Assessing the quality of reports of randomized clinical t rials: Is blinding necessary ?. Control Clinic Trials 1996, 17:1-12.
15. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558. 10.1002/sim.1186, 12111919.
16. Harris JE, Ryan L, Hoover HC, Stuart RK, Oken MM, Benson AB, Mansour E, Haller DG, Manola J, Hanna MG. Adjuvant Active Specific Immunotherapy for Stage II and III Colon Cancer With an Autologous Tumor Cell Vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000, 18:148-153.
17. Uyl-de Groot CA, Vermorken JB, Hanna MG, Verboom P, Groot MT, Bonsel GJ, Meijer CJ, Pinedo HM. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benets. Vaccine 2005, 23:2379-2387. 10.1016/j.vaccine.2005.01.015, 15755632.
18. Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother 2009, 58:61-69. 10.1007/s00262-008-0526-1, 18488223.
19. Riethmüller G, Holz E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R. Monoclonal Antibody Therapy for Resected Dukes' Colorectal Cancer:Seven-Year Outcome of a Multicenter Randomized Trial. J Clin Oncol 1998, 16:1788-1794.
20. Liang W, Wang H, Sun TM, Yao WQ, Chen LL, Jin Y, Li CL, Meng FJ, et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive traet. World J Gastroenterol 2003, 9:495-498.
21. Tarasov VA, Filatov MV, Kisliakova TV, Noskov FS, Koloskov AV, Stavrovietski VV, Onikienko SB, Kletchikov VZ, Lvov IV, Yu Varfolomeeva E, Blizniukov OP, Levina VV, Kiselevski MV. Combined Surgical and Immunotherapeutic Treatment of Patients with Fourth Stage Colon Cancer. Hybridoma 1999, 18:99-102. 10.1089/hyb.1999.18.99, 10211796.
22. Bhattachary-Chatterjee M, Nath Baral R, Chatterjee SK, Das R, Zeytin H, Chakraborty M, Foon KA. Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple- epitope antigen vaccine. Cancer Immunol Immunother 2000, 49:133-141. 10.1007/s002620050612, 10881692.
23. Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL, Shaw DR, LoBuglio AF. Safety and Immunogenicity of a DNA Vaccine Encoding Carcinoembryonic Antigen and Hepatitis B Surface Antigen in Colorectal Carcinoma Patients. Clin Cancer Res 2002, 8:2782-2787.
24. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001, 98:8809-8814. 10.1073/pnas.141226398, 37517, 11427731.
25. Hörig H, Lee DS, Conkright W, Divito J, Hasson H, LaMare M, Rivera A, Park D, Tine J, Guito K, Tsang KW, Schlom J, Kaufman HL. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000, 49:504-514.
26. Itoh T, Ueda Y, Kawashima I, Nukaya I, Fujiwara H, Fuji N, Yamashita T, Yoshimura T, Okugawa K, Iwasaki T, Ideno M, Takesako K, Mitsuhashi M, Orita K, Yamagishi H. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother 2002, 51:99-106. 10.1007/s00262-001-0257-z, 11904734.
27. Liang W, Wang H, Sun TM, Yao WQ, Chen LL, Jin Y, Li CL, Meng FJ. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol 2003, 9:495-498.
28. Liu KJ, Wang CC, Chen LT, Cheng AL, Lin DT, Wu YC, Yu WL, Hung YM, Yang HY, Juang SH, Whang-Peng J. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res 2004, 10:2645-2651. 10.1158/1078-0432.CCR-03-0430, 15102666.
29. Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KY, Schlom J. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Onco 2000, 18:3964-3973.
30. Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005, 23:720-731. 10.1200/JCO.2005.10.206, 15613691.
31. Matsuda K, Tsunoda T, Tanaka H, Umano Y, Tanimura H, Nukaya I, Takesako K, Yamaue H. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol Immunother 2004, 53:609-616. 10.1007/s00262-003-0491-7, 14735319.
32. Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, Muto A, Okouchi S, Isomoto H, Shirouzu K, Yamana H, Itoh K. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 2001, 7:3950-3962.
33. Morse MA, Nair SK, Mosca PJ, Hobeika AC, Clay TM, Deng Y, Boczkowski D, Proia A, Neidzwiecki D, Clavien PA, Hurwitz HI, Schlom J, Gilboa E, Lyerly HK. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003, 21:341-349. 10.1081/CNV-120018224, 12901279.
34. Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 2005, 11:3017-3024. 10.1158/1078-0432.CCR-04-2172, 15837756.
35. Rains N, Cannan RJ, Chen W, Stubbs RS. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology 2001, 48:347-351.
36. Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Akiyoshi T, Mori M. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001, 7:2277-2284.
37. Sato Y, Maeda Y, Shomura H, Sasatomi T, Takahashi M, Une Y, Kondo M, Shinohara T, Hida N, Katagiri K, Sato K, Sato M, Yamada A, Yamana H, Harada M, Itoh K, Todo S. A phase I trial of cytotoxic T- lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br J Cancer 2004, 90:1334-1342. 10.1038/sj.bjc.6601711, 2409683, 15054451.
38. Tsuruma T, Hata F, Torigoe T, Furuhata T, Idenoue S, Kurotaki T, Yamamoto M, Yagihashi A, Ohmura T, Yamaguchi K, Katsuramaki T, Yasoshima T, Sasaki K, Mizushima Y, Minamida H, Kimura H, Akiyama M, Hirohashi Y, Asanuma H, Tamura Y, Shimozawa K, Sato N, Hirata K. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004, 2:19-24. 10.1186/1479-5876-2-19, 446218, 15193151.
39. Ueda Y, Itoh T, Nukaya I, Kawashima I, Okugawa K, Yano Y, Yamamoto Y, Naitoh K, Shimizu K, Imura K, Fuji N, Fujiwara H, Ochiai T, Itoi H, Sonoyama T, Hagiwara A, Takesako K, Yamagishi H. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol 2004, 24:909-917.
40. von Mehren M, Arlen P, Tsang KY, Rogatko A, Meropol N, Cooper HS, Davey M, McLaughlin S, Schlom J, Weiner LM. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 2000, 6:2219-2228.
41. Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S, Vázquez J, Lasalvia-Galante E, Golomar W, Larrañga J. Advanced Colon Cancer: Antiprogressive Immunotherapy Using an Autologous Hemoderivative. Med Oncol 2006, 23:91-104. 10.1385/MO:23:1:91, 16645234.
42. Burgdorf SK, Fischer A, Myschetzky PS, Munksgaard SB, Zocca MB, Claesson MH, Rosenberg J. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. oncol Rep 2008, 20:1305-1311.
43. Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan MG, Myers KA, Drury N, Kingsman SM, Hawkins RE, Carroll MW. Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Induces Immune Responses which Correlate with Disease Control: A Phase I/II Trial. Clin Cancer Res 2006, 12:3416-3424. 10.1158/1078-0432.CCR-05-2732, 16740766.
44. Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, Valentijn AR, Oostendorp J, Fathers LM, Nijman HW, Drijfhout JW, van de Velde CJ, van der Melief CJ. Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer. Clin Cancer Res 2009, 15:1086-1091. 10.1158/1078-0432.CCR-08-2227, 19188184.
45. Tamir A, Basagila E, Kagahzian A, Jiao L, Jensen S, Nicholls J, Tate P, Stamp G, Farzaneh F, Harrison P, Stauss H, George AJ, Habib N, Lechler RI, Lombardi G. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunol Immunother 2007, 56:2003-2016. 10.1007/s00262-007-0299-y, 17333181.
46. Dai S, Wei D, Wu Z, Zhou X, Wei X, Huang H, Li G. Phase I Clinical Trial of Autologous Ascites-derived Exosomes Combined With GM-CSF for Colorectal Cancer. Mol Ther 2008, 164:782-790.
47. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L. Vaccination of Metastatic Colorectal Cancer Patients With Matured Dendritic Cells Loaded With Multiple Major Histocompatibility Complex Class I Peptides. J Immunother 2007, 30:762-772. 10.1097/CJI.0b013e318133451c, 17893568.
48. Okaji Y, Tsuno NH, Tanaka M, Yoneyama S, Matsuhashi M, Kitayama J, Saito S, Nagura Y, Tsuchiya T, Yamada J, Tanaka J, Yoshikawa N, Nishikawa T, Shuno Y, Todo T, Saito N, Takahashi K. Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Eur J Cancer 2008, 44:383-390. 10.1016/j.ejca.2007.10.018, 18060766.
49. Seledtsov VI, Niza NA, Felde MA, Shishkov AA, Samarin DM, Seledtsova GV, Seledtsov DV. Xenovaccinotherapy for colorectal cancer. Biomed Pharmacother 2007, 61:125-130. 10.1016/j.biopha.2006.09.016, 17258887.
50. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, Park C, Ahn YJ, Daneshmand M, Rhee BG, Pinedo HM, Bell JC, Kirn DH. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008, 9:533-542. 10.1016/S1470-2045(08)70107-4, 18495536.
51. Wittig B, Märten A, Dorbic T, Weineck S, Min H, Niemitz S, Trojaneck B, Flieger D, Kruopis S, Albers A, Löffel J, Neubauer A, Albers P, Müller S, Sauerbruch T, Bieber T, Huhn D, Schmidt-Wolf IG. Therapeutic Vaccination against Metastatic Carcinoma by Expression-Modulated and Immunomodified Autologous Tumor Cells: A First Clinical Phase I/II Trial. Hum Gene Ther 2001, 12:267-278. 10.1089/10430340150218404, 11177563.
52. Menon AG, Kuppen PJ, van der Burg SH, Offringa R, Bonnet MC, Harinck BI, Tollenaar RA, Redeker A, Putter H, Moingeon P, Morreau H, Melief CJ, van de Velde CJ. Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients. Cancer Gene Ther 2003, 10:509-517. 10.1038/sj.cgt.7700600, 12833131.
53. Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson A, Galanis E, Uprichard M, Omer C, Bycott P, Hackman RC, Shields AF. Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer. J Clin Oncol 2003, 21:1498-1504. 10.1200/JCO.2003.09.114, 12697873.
54. Waterston AM, Gumbrell L, Bratt T, Waller S, Gustav-Aspland J, L'hermenier C, Bellenger K, Campbell M, Powles T, Highley M, Bower M, Mouritsen S, Feldmann M, Coombes RC. Phase I study of TNFalpha AutoVaccIne in patients with metastatic cancer. Cancer Immunol Immunother 2005, 54:848-857. 10.1007/s00262-005-0661-x, 15754205.
55. Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK. Phase I Study of Immunization with Dendritic Cells Modified with Fowlpox Encoding Carcinoembryonic Antigen and Costimulatory Molecules. Clin Cancer Res 2005, 11:3017-3024. 10.1158/1078-0432.CCR-04-2172, 15837756.
56. Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, Bornhäuser M. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother 2006, 55:268-276. 10.1007/s00262-005-0021-x, 16034561.
57. Liu KJ, Wang CC, Chen LT, Cheng AL, Lin DT, Wu YC, Yu WL, Hung YM, Yang HY, Juang SH, Whang-Peng J. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A 2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res 2004, 10:2645-2651. 10.1158/1078-0432.CCR-03-0430, 15102666.
58. Zbar AP, Thomas H, Wilkinson RW, Wadhwa M, Syrigos KN, Ross EL, Dilger P, Allen-Mersh TG, Kmiot WA, Epenetos AA, Snary D, Bodmer WF. Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study. Int J Colorectal Dis 2005, 20:403-414. 10.1007/s00384-004-0726-x, 15864608.
59. Neidhart J, Allen KO, Barlow DL, Carpenter M, Shaw DR, Triozzi PL, Conry RM. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Vaccine 2004, 22:773-780. 10.1016/j.vaccine.2003.08.021, 14741172.
60. Conry RM, Khazaeli MB, Saleh MN, Allen KO, Barlow DL, Moore SE, Craig D, Arani RB, Schlom J, LoBuglio AF. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res 1999, 5:2330-2337.
61. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999, 5:1331-1338.
62. Samonigg H, Wilders-Truschnig M, Kuss I, Plot R, Stöger H, Schmid M, Bauernhofer T, Tiran A, Pieber T, Havelec L, Loibner H. A double-blind randomized-phase II trial comparing immunization with antiidiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer. J Immunother 1999, 22:481-488. 10.1097/00002371-199911000-00002, 10570746.
63. Sobol RE, Shawler DL, Carson C, Van Beveren C, Mercola D, Fakhrai H, Garrett MA, Barone R, Goldfarb P, Bartholomew RM, Brostoff S, Carlo DJ, Royston I, Gold DP. Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study. Clin Cancer Res 1999, 5:2359-2365.
64. Woodlock TJ, Sahasrabudhe DM, Marquis DM, Greene D, Pandya KJ, McCune CS. Active specific immunotherapy for metastatic colorectal carcinoma: phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha. J Immuno ther 1999, 22:251-259.
65. Hanna MG, Hoover HC, Pinedo HM, Finer M. Active Specific Immunotherapy with Autologous Tumor Cell Vaccines for Stage II Colon Cancer: Logistics, Efficacy, Safety and Immunological Pharmacodynamics. Hum Vaccin 2006, 2:185-191.
66. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, Hermans J, van Krieken JH, Cornelisse CJ, Tollenaar RA. Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998, 339:223-228. 10.1056/NEJM199807233390403, 9673300.
67. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
68. von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001, 7:1181-1191.
69. Beck K, Blansfield J, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006, 24:2283-2289. 10.1200/JCO.2005.04.5716, 2140223, 16710025.
70. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006, 6:295-307. 10.1038/nri1806, 16557261.
71. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2006, 56:641-648. 10.1007/s00262-006-0225-8, 16960692.
72. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005, 28:582-592. 10.1097/01.cji.0000175468.19742.10, 1533764, 16224276.
73. O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, Gause B, Pittaluga S, Neelapu S, Brown M, Fleisher TA, Gulley JL, Schlom J, Nussenblatt R, Albert P, Davis TA, Lowy I, Petrus M, Waldmann TA, Janik JE. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 2007, 13:958-964.
74. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005, 115:3623-3633. 10.1172/JCI25947, 1288834, 16308572.
75. Idenoue S, Hirohashi Y, Torigoe T, Sato Y, Tamura Y, Hariu H, Yamamoto M, Kurotaki T, Tsuruma T, Asanuma H, Kanaseki T, Ikeda H, Kashiwagi K, Okazaki M, Sasaki K, Sato T, Ohmura T, Hata F, Yamaguchi K, Hirata K, Sato N. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 2005, 11:1474-8142. 10.1158/1078-0432.CCR-03-0817, 15746049.
76. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997, 15:617-648. 10.1146/annurev.immunol.15.1.617, 9143702.